Clinical Trials

NCT Number: NCT05345444 Phase: Not Applicable Trial Summary: This is a single-site trial for 42 subjects with intermediate risk prostate cancer who undergo Irreversible Electroporation (IRE) followed by Magnetic Resonance guided Radiotherapy – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Weill Medical College of Cornell University Acronym: RTIRE

NCT Number: NCT05327452 Phase: NA Trial Summary: The purpose of this research is to determine whether a 16 week, home-based, aerobic and resistance exercise intervention will increase physical activity levels in Black and Hispani – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Dana-Farber Cancer Institute Acronym:

NCT Number: NCT05327465 Phase: NA Trial Summary: The purpose of this research is to determine whether a 16-week culturally tailored, technology-based, aerobic and resistance exercise intervention improves cardiovascular risk fact – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Dana-Farber Cancer Institute Acronym:

NCT Number: NCT05301114 Phase: NA Trial Summary: The objective of the proposed study is to scale social risk factor screening and referral for cancer survivors and to solidify information exchange between clinical and community s – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Medstar Health Research Institute Acronym:

NCT Number: NCT05252390 Phase: Phase 1|Phase 2 Trial Summary: NUV-868-01 is a first-in-human, open-label, Phase 1/2 dose escalation and expansion study in patients with advanced solid tumors. The Phase 1 and 1b portions include patients with – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Nuvation Bio Inc. Acronym:

NCT Number: NCT05268666 Phase: Phase 1|Phase 2 Trial Summary: The purpose of this study is to determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of JBI-802 in patients with Advanced Solid Tumors.The efficacy of the – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Jubilant Therapeutics Inc. Acronym:

NCT Number: NCT05293496 Phase: Phase 1 Trial Summary: Study CP-MGC018-02 is a study of vobramitamab duocarmazine (MGC018) in combination with lorigerlimab. The study is designed to characterize safety, tolerability, pharmacokinetics ( – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): MacroGenics Acronym:

NCT Number: NCT05311527 Phase: PHASE1 Trial Summary: Confirming safety of combining UroLift System prior to SAbR for patients with newly diagnosed prostate cancer and a history of BPH, by measuring the acute complication rate of UroL – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Texas Southwestern Medical Center Acronym:

NCT Number: NCT05223803 Phase: Phase 2 Trial Summary: This research is being done to determine if we can improve the outcome of prostate cancer patients who have failed primary treatment – surgery or local radiation to the prostate – – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Maryland, Baltimore Acronym:

NCT Number: NCT05215574 Phase: Phase 1 Trial Summary: Study of NGM831 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): NGM Biopharmaceuticals, Inc|Merck Sharp & Dohme LLC Acronym: